Total Valuation
Rasna Therapeutics has a market cap or net worth of $385.91K. The enterprise value is $521.89K.
Market Cap$385.91K
Enterprise Value$521.89K
Share Statistics
Rasna Therapeutics has 771,811,340 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding771,811,340
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Rasna Therapeutics’s return on equity (ROE) is 2.27 and return on invested capital (ROIC) is 242.87%.
Return on Equity (ROE)2.27
Return on Assets (ROA)-46.45
Return on Invested Capital (ROIC)242.87%
Return on Capital Employed (ROCE)2.17
Revenue Per Employee0.00
Profits Per Employee-4.44M
Employee Count1
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Rasna Therapeutics is ―. Rasna Therapeutics’s PEG ratio is 0.11.
PE Ratio―
PS Ratio0.00
PB Ratio-5.91
Price to Fair Value-5.91
Price to FCF-1.36K
Price to Operating Cash Flow-33.94
PEG Ratio0.11
Income Statement
In the last 12 months, Rasna Therapeutics had revenue of 0.00 and earned -4.44M in profits. Earnings per share was >-0.01.
Revenue0.00
Gross Profit0.00
Operating Income-4.24M
Pretax Income-4.44M
Net Income-4.44M
EBITDA-380.00K
Earnings Per Share (EPS)>-0.01
Cash Flow
In the last 12 months, operating cash flow was -66.42K and capital expenditures 4.00, giving a free cash flow of -66.42K billion.
Operating Cash Flow-66.42K
Free Cash Flow-66.42K
Free Cash Flow per Share>-0.01
Dividends & Yields
Rasna Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.45
52-Week Price Change0.00%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)100.00
Average Volume (3m)0.00
Important Dates
Rasna Therapeutics upcoming earnings date is May 10, 2018, After Close (Confirmed).
Last Earnings DateInvalid Date
Next Earnings DateMay 10, 2018
Ex-Dividend Date―
Financial Position
Rasna Therapeutics as a current ratio of 0.05, with Debt / Equity ratio of -10.79%
Current Ratio0.05
Quick Ratio0.06
Debt to Market Cap0.02
Net Debt to EBITDA-0.36
Interest Coverage Ratio-19.90
Taxes
In the past 12 months, Rasna Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Rasna Therapeutics EV to EBITDA ratio is -30.78, with an EV/FCF ratio of -1.37K.
EV to Sales0.00
EV to EBITDA-30.78
EV to Free Cash Flow-1.37K
EV to Operating Cash Flow-1.37K
Balance Sheet
Rasna Therapeutics has $1.39K in cash and marketable securities with $303.96K in debt, giving a net cash position of -$302.57K billion.
Cash & Marketable Securities$1.39K
Total Debt$303.96K
Net Cash-$302.57K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share>-$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Rasna Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―